Abstract
Limited data are available regarding contemporary multiple myeloma (MM) treatment practices in Latin America. In this retrospective cohort study, medical records were reviewed for a multinational cohort of 1103 Latin American MM patients (median age, 61 years) diagnosed in 2008-2015 who initiated first-line therapy (LOT1). Of these patients, 33·9% underwent autologous stem cell transplantation (ASCT). During follow-up, 501 (45·4%) and 129 (11·7%) patients initiated second- (LOT2) and third-line therapy (LOT3), respectively. In the LOT1 setting, from 2008 to 2015, there was a decrease in the use of thalidomide-based therapy, from 66·7% to 42·6%, and chemotherapy from, 20·2% to 5·9%, whereas use of bortezomib-based therapy or bortezomib + thalidomide increased from 10·7% to 45·5%. Bortezomib-based therapy and bortezomib + thalidomide were more commonly used in ASCT patients and in private clinics. In non-ASCT and ASCT patients, median progression-free survival (PFS) was 15·0 and 31·1 months following LOT1 and 10·9 and 9·5 months following LOT2, respectively. PFS was generally longer in patients treated with bortezomib-based or thalidomide-based therapy versus chemotherapy. These data shed light on recent trends in the management ...Continue Reading
References
Apr 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip R GreippJan Westin
May 3, 2008·Haematologica·Vania T M HungriaUNKNOWN International Myeloma Working Group Latin America
Jul 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pieter SonneveldHartmut M Goldschmidt
Oct 26, 2013·Leukemia·S K KumarS V Rajkumar
Jul 18, 2014·The Lancet Oncology·Milena SantUNKNOWN EUROCARE-5 Working Group
Aug 5, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio PalumboPhilippe Moreau
Sep 27, 2015·Revista brasileira de hematologia e hemoterapia·Carolina MinnicelliTelma Maria Araújo Moura Lemos
Nov 3, 2015·The Lancet Oncology·Kathrin Strasser-WeipplPaul E Goss
Nov 7, 2016·Annals of Hematology·Vania T M HungriaUNKNOWN International Myeloma Working Group Latin America
Jan 8, 2017·Seminars in Oncology·Dickran Kazandjian, Ola Landgren
Feb 28, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chrissy H Y van Beurden-TanPieter Sonneveld
Apr 30, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P MoreauUNKNOWN ESMO Guidelines Committee
Feb 21, 2018·Cancer·Luz Tarín-ArzagaDavid Gómez-Almaguer
Mar 25, 2018·Cancer Medicine·Maria Paula CuradoDyego L B Souza
May 26, 2018·JAMA Oncology·Andrew J CowanChristina Fitzmaurice
Oct 10, 2018·Clinical Lymphoma, Myeloma & Leukemia·Roberto José Pessoa de Magalhães FilhoBrian Durie
Oct 16, 2018·Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi·T H LamR Ching
May 4, 2018·HemaSphere·Silvia G R VerelstPieter Sonneveld
Jul 1, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P MoreauUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Citations
Aug 6, 2019·British Journal of Haematology·Jorge J Castillo
Aug 28, 2020·Leukemia & Lymphoma·Camila PeñaDorotea Fantl
Oct 18, 2020·Advances in Therapy·Vania HungriaMariana Fernandez
Jan 9, 2021·Clinical Lymphoma, Myeloma & Leukemia·Cesar Vargas-SerafinChristianne Bourlon
Jan 15, 2021·Scientific Reports·Yanfang LiuHsin-An Hou
Sep 25, 2020·Hematology, Transfusion and Cell Therapy·Edvan de Queiroz CrusoéLuciana Barreto Herriot
May 29, 2021·Future Oncology·Fernando PetracciMarwan Ghosn
Jun 6, 2021·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Lucas Lacerda de SouzaOslei Paes de Almeida